Elastagen: skinnovation

Enabled by the AMMRF at the University of Sydney

Elastagen Pty Ltd is a clinical-stage medical-device company that is pioneering Elastatherapy™, which uses the human protein elastin to naturally repair and augment the skin. The company has arisen out of patented research conducted by Prof. Tony Weiss’s group and the first clinical trials have demonstrated the biocompatability and safety of their synthetic human elastin in human subjects. Prof. Weiss’s work on elastin for burns treatment was highlighted in the 2010 AMMRF Profile. Elastagen is a venture-backed private company based in Sydney. Investors include ATP Innovations, Brandon Capital and GBS Ventures.


Related Stories

Hazer Group live on ASX

Hazer Group was established in 2010 from technology developed at UWA to produce clean hydrogen and high-grade synthetic graphite from natural gas and iron ore. Its development depended on AMMRF microscopy @ UWA. They have announced the successful ...

burn victim

Fast-tracking elastin to market

Prof. Tony Weiss from the University of Sydney in conjunction with Elastagen Pty Ltd has been awarded a $1million Translation Award from the Wellcome Trust to fast track their elastin-based synthetic skin to clinical trials. They will refine and ...


Nanopatch to tackle polio

The World Health Organization (WHO) is to provide funding to spin-out company, Vaxxas, so it can develop the NanopatchTM for polio vaccination. WHO will fund pre-clinical studies and the development of good manufacturing practices. Following the ...